Readystate Asset Management’s Janux Therapeutics JANX Stock Holding History

Readystate Asset Management’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-109,425	Closed	-$1.52M	–	978
2026 Q1	$1.52M	Sell	109,425 -776,470	-88%	-$10.6M	0.07%	184
2025 Q4	$12.2M	Sell	885,895 -74,484	-8%	-$1.75M	0.5%	51
2025 Q3	$23.5M	Buy	960,379 +264,423	+38%	+$6.44M	1%	23
2025 Q2	$16.1M	Buy	695,956 +419,396	+152%	+$11.1M	0.49%	47
2025 Q1	$7.47M	Sell	276,560 -63,079	-19%	-$2.38M	0.25%	73
2024 Q4	$18.2M	Buy	339,639 +307,304	+950%	+$16.3M	0.56%	36
2024 Q3	$1.47M	Buy	+32,335	New	+$1.41M	0.03%	383

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Readystate Asset Management's JANX Position: Q2 2026 in Review

Readystate Asset Management sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 109,425 shares — an estimated $1.52M sold.

Readystate Asset Management first reported a position in JANX in Q3 2024 and held it in 7 quarters. The position peaked at $23.5M in Q3 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Readystate Asset Management reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
Readystate Asset Management sold 109,425 Janux Therapeutics shares in Q2 2026, an estimated $1.52M.
Readystate Asset Management first reported a position in Janux Therapeutics in Q3 2024 and held it in 7 quarters.
Readystate Asset Management's Janux Therapeutics position peaked at $23.5M in Q3 2025.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Readystate Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.